Galera Therapeutics shares are trading lower after the company announced it received a Complete Response Letter from the FDA for avasopasem manganese.
Portfolio Pulse from Benzinga Newsdesk
Galera Therapeutics has received a Complete Response Letter from the FDA for avasopasem manganese, causing its shares to trade lower.
August 10, 2023 | 12:53 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Galera Therapeutics' stock is trading lower due to the FDA's Complete Response Letter for avasopasem manganese.
The FDA's Complete Response Letter is typically a form of communication that notifies a company that the agency will not approve a drug in its current form. This news is directly related to Galera Therapeutics and its drug avasopasem manganese, causing a negative impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100